MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Затворен

СекторЗдравеопазване

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	-0.79% downside

Настроения в новините

By Acuity

50%

148 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

131.5 / 131.92 Подкрепа & съпротива

Intra-Cellular Therapies Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12.04.2026 г., 23:38 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12.04.2026 г., 23:38 ч. UTC

Пазарно говорене

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12.04.2026 г., 23:31 ч. UTC

Пазарно говорене

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12.04.2026 г., 23:09 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12.04.2026 г., 23:06 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.04.2026 г., 23:06 ч. UTC

Пазарно говорене

Australian Dollar Ripe for a Downward Correction -- Market Talk

12.04.2026 г., 22:56 ч. UTC

Значими събития в новините

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12.04.2026 г., 22:54 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12.04.2026 г., 22:53 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12.04.2026 г., 22:51 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12.04.2026 г., 22:50 ч. UTC

Пазарно говорене

Значими събития в новините

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12.04.2026 г., 22:37 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

11.04.2026 г., 00:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Big Yachts, Big Bucks -- Barrons.com

10.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10.04.2026 г., 21:01 ч. UTC

Печалби

Cango Inc.: Files Annual Report on Form 20-F With SEC

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 20:31 ч. UTC

Пазарно говорене

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10.04.2026 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

10.04.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Intra-Cellular Therapies Inc Прогноза

Ценова цел

By TipRanks

-0.79% надолу

12-месечна прогноза

Среден 130.83 USD -0.79%

Висок 132 USD

Нисък 118 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Intra-Cellular Therapies Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Intra-Cellular Therapies Inc през последните 3 месеца.

Техническа оценка

By Trading Central

131.5 / 131.92Подкрепа & съпротива

There is one bullish event.

There are no events.

Настроение

By Acuity

148 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.